Raymond James & Associates Verastem, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VSTM
# of Institutions
5Shares Held
297KCall Options Held
0Put Options Held
0-
Telemetry Investments, L.L.C. New York, NY225KShares$897,7500.14% of portfolio
-
Beaumont Financial Partners, LLC48KShares$191,5200.0% of portfolio
-
Eaton Vance Management Boston, MA20KShares$79,8000.0% of portfolio
-
American Portfolios Advisors Holbrook, NY2.99KShares$11,9100.0% of portfolio
-
Brewin Dolphin Wealth Management LTD Conskleagh, Dublin, L21.07KShares$4,2850.0% of portfolio
About Verastem, Inc.
- Ticker VSTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 210,000,000
- Market Cap $838M
- Description
- Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...